The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
NCT ID: NCT04433845
Last Updated: 2022-10-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
15 participants
INTERVENTIONAL
2021-03-01
2023-04-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
NCT06943573
Psilocybin Therapy for Depression in Bipolar II Disorder
NCT05065294
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
NCT06506019
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
NCT06706232
Scopolamine in Bipolar Depression
NCT04211961
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Psilocybin
25mg of Psilocybin
Psilocybin
Open-label
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Psilocybin
Open-label
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
COMPASS Pathways
INDUSTRY
Sheppard Pratt Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Scott T. Aaronson, M.D
Director, Clinical Research Programs
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott Aaronson, MD
Role: PRINCIPAL_INVESTIGATOR
Sheppard Pratt Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sheppard Pratt
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14947483
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.